Audrey Belot

Scientist and emerging leader in translational research with 5+ years of postdoctoral experience in heme/iron metabolism, a doctoral background in liver pathology and a master background studying the role of mesotrypsin in bowel diseases. Skilled in bridging fundamental research with clinical relevance in rare disease biology, including mechanisms of organ dysfunction and inflammation. Demonstrated ability to lead complex research projects, analyze preclinical data, and contribute to multidisciplinary collaborations. Strong publication record, deep expertise in molecular and cellular mechanisms of disease, and a solid foundation in drug development concepts. Now seeking to transition into a strategic, cross-functional role where scientific insight, regulatory awareness, and collaborative leadership can contribute to advancing therapeutic programs in pulmonary and liver-related rare diseases such as AATD.

2024 Cooley’s Anemia Foundation fellowship obtained as a PI – USA (1 year, $50,000)

2022 Type B CCEH U24 Grant obtained as a PI - Center of Excellence in Hematology, Utah, USA (1 year, $75,000)

2021 Post-doctoral fellowship by the French Hematology Society obtained as PI (6 months)

2019 End-of-thesis scholarship by the French Hematology Society obtained as PI (1 year)

• Belot A, Puy H, Hamza I, Bonkovsky H, Update on heme biosynthesis, tissue-specific regulation, heme transport, relation to iron metabolism and cellular energy, Liver Int, 09/2024, 44, 9, 2235-2250
• Wake M*, Palin A*, Belot A*, Berger M, Lorgouilloux M, Bichon M, Papworth J, Bayliss L, Grimshaw B, Rynkiewicz N, Paterson J, Poindron A, Spearing E, Carter E, Hudson R, Campbell M, Petzer V, Besson Fournier C, Latour C, Largounez A, Goubeyre O, Fay A, Coppin H, Roth MP, Theurl I, Germaschewski V, Meynard D, A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates and splenomegaly in β-thalassemic mice, Blood Advances, 04/2024, 8, 8, 1898-1907
• Belot A, Gourbeyre O, Rubio A, Besson-Fournier C, Latour C, Gallitz I, Montagner A, Polizzi A, Régnier M, Smati S, Steinbicker AU, Guillou H, Roth MP, Coppin H, Meynard D, ER stress controls iron metabolism through TMPRSS6 repression and hepcidin mRNA stabilization by RNA-binding protein HuR, Haematologica, 04/2021, 106, 4, 1202-1206
• Belot A, Gourbeyre O, Fay A, Palin A, Besson-Fournier C, Latour C, Hopkins CR, Tidmarsh GF, Coppin C, Roth MP, Ritter MR, Hong CC, Meynard D, LJ000328, a novel ALK3 kinase inhibitor, represses hepcidin and significantly improves the phenotype of IRIDA, Haematologica, 08/2020, 105, 8, e385-e388